降低全球心血管疾病风险：通过改变生活方式和药物治疗。
Reducing global risk for cardiovascular disease: using lifestyle changes and pharmacotherapy.
作者信息
Cheng Alan, Braunstein Joel B, Dennison Cheryl, Nass Caitlin, Blumenthal Roger S
机构信息
The Ciccarone Center for Prevention of Heart Disease, The Johns Hopkins Hospital, Baltimore, Maryland, USA.
出版信息
Clin Cardiol. 2002 May;25(5):205-12. doi: 10.1002/clc.4950250503.
Abstract
Cardiovascular disease (CVD) is the leading cause of death and disability in industrialized societies, due in large part to the lack of a comprehensive approach to control the risk factors for atherosclerosis. One strategy for reducing an individual's global CVD risk relies on a targeted approach that modifies each of the major independent risk factors prevalent in both symptomatic (secondary prevention) and asymptomatic (primary prevention) patients. These interventions include lipid lowering, smoking cessation, blood pressure control, glycemic control, regular exercise, and the use of various medications. This review offers an evidence-based strategy toward reducing an individual's global risk for CVD by addressing the modifiable, major independent risk factors.
摘要
心血管疾病（CVD）是工业化社会中导致死亡和残疾的主要原因，这在很大程度上归因于缺乏控制动脉粥样硬化风险因素的综合方法。降低个体整体心血管疾病风险的一种策略依赖于一种针对性方法，该方法可改变有症状（二级预防）和无症状（一级预防）患者中普遍存在的每一个主要独立风险因素。这些干预措施包括降脂、戒烟、血压控制、血糖控制、定期锻炼以及使用各种药物。本综述通过探讨可改变的主要独立风险因素，提供了一种基于证据的策略来降低个体患心血管疾病的整体风险。
相似文献
1
Reducing global risk for cardiovascular disease: using lifestyle changes and pharmacotherapy.
Clin Cardiol. 2002 May;25(5):205-12. doi: 10.1002/clc.4950250503.
2
AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology.
J Am Coll Cardiol. 2001 Nov 1;38(5):1581-3. doi: 10.1016/s0735-1097(01)01682-5.
3
[Cardiovascular risk factors and their prevention].
Rev Prat. 2002 Dec 15;52(20):2293-300.
4
Lifestyles and Cardiovascular Prevention in Childhood and Adolescence.
Pediatr Cardiol. 2019 Aug;40(6):1113-1125. doi: 10.1007/s00246-019-02152-w. Epub 2019 Jul 24.
5
Reducing the global burden of cardiovascular disease: the role of risk factors.
Prev Cardiol. 2002 Fall;5(4):188-99. doi: 10.1111/j.1520-037x.2002.00564.x.
6
Keeping the diabetic heart healthy.
Aust Fam Physician. 2005 Jun;34(6):441-5.
7
[Role of diet in cardiovascular prevention].
Ann Med Interne (Paris). 2001 Apr;152(3):194-7.
8
Reducing cardiovascular risk in diabetes. Which factors to modify first?
Postgrad Med. 2001 Apr;109(4):26-30, 33-6. doi: 10.3810/pgm.2001.04.904.
9
Lifestyle modifications for the prevention and treatment of cardiovascular disease: an evidence-based approach.
Mo Med. 2004 May-Jun;101(3):222-6.
10
Development of a cost-effective CVD prediction model using lifestyle factors. A cohort study in Pakistan.
Afr Health Sci. 2020 Jun;20(2):849-859. doi: 10.4314/ahs.v20i2.39.
引用本文的文献
1
Egg consumption and risk of cardiovascular disease: a PERSIAN cohort-based study.
BMC Cardiovasc Disord. 2023 Nov 30;23(1):588. doi: 10.1186/s12872-023-03621-0.
2
Metabolic Syndrome and Cognitive Functions in Schizophrenia-Implementation of Dietary Intervention.
Front Psychiatry. 2020 Apr 30;11:359. doi: 10.3389/fpsyt.2020.00359. eCollection 2020.
3
Prevalence, risk awareness and health beliefs of behavioural risk factors for cardiovascular disease among university students in nine ASEAN countries.
BMC Public Health. 2018 Feb 13;18(1):237. doi: 10.1186/s12889-018-5142-1.
4
Prevalence and correlates of coronary heart disease: first population-based study in Lebanon.
Vasc Health Risk Manag. 2016 Mar 17;12:75-84. doi: 10.2147/VHRM.S97252. eCollection 2016.
5
Are cardiovascular risk factors associated with verbal learning and memory impairment in patients with schizophrenia? A cross-sectional study.
Cardiovasc Psychiatry Neurol. 2012;2012:204043. doi: 10.1155/2012/204043. Epub 2012 Nov 19.
6
The socioeconomic burden of coronary heart disease in Korea.
J Prev Med Public Health. 2012 Sep;45(5):291-300. doi: 10.3961/jpmph.2012.45.5.291. Epub 2012 Sep 28.
7
Is the distinction between Alzheimer's disease and vascular dementia possible and relevant?
Dialogues Clin Neurosci. 2003 Mar;5(1):7-15. doi: 10.31887/DCNS.2003.5.1/rravonaspringer.
8
Cardiovascular health among adults in Syria: a model from developing countries.
Ann Epidemiol. 2007 Sep;17(9):713-20. doi: 10.1016/j.annepidem.2007.03.016. Epub 2007 Jun 6.
本文引用的文献
1
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
JAMA. 2001 May 16;285(19):2486-97. doi: 10.1001/jama.285.19.2486.
2
Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE).
Lancet. 2000 Jul 22;356(9226):279-84. doi: 10.1016/s0140-6736(00)02502-2.
3
Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
Circulation. 2000 Sep 5;102(10):1139-44. doi: 10.1161/01.cir.102.10.1139.
4
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
Lancet. 2000 Jul 29;356(9227):366-72. doi: 10.1016/S0140-6736(00)02527-7.
5
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
BMJ. 2000 Aug 12;321(7258):405-12. doi: 10.1136/bmj.321.7258.405.
6
Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity.
JAMA. 2000 Jul 19;284(3):311-8. doi: 10.1001/jama.284.3.311.
7
Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.
Circulation. 2000 Jul 11;102(2):157-65. doi: 10.1161/01.cir.102.2.157.
8
Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?
Arch Intern Med. 2000 Jul 10;160(13):1905-11. doi: 10.1001/archinte.160.13.1905.
9
Primary prevention of coronary heart disease in women through diet and lifestyle.
N Engl J Med. 2000 Jul 6;343(1):16-22. doi: 10.1056/NEJM200007063430103.
10
Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial.
BMJ. 2000 Jul 1;321(7252):13-7. doi: 10.1136/bmj.321.7252.13.
Zotero 插件